Commentary

TAG Paper: Observations on Drug Pricing and Innovation in Japan

Full Paper (English): TAG Paper: Observations on Drug Pricing and Innovation in Japan ENG

Full Paper (Japanese): TAG Paper: Observations on Drug Pricing and Innovation in Japan JPN

Key Findings

As the Government of Japan (GOJ) seeks to re-invigorate Japan’s pharmaceutical industry as a sector for innovation and growth, it can make impactful changes to specific pricing policies that will support Japanese patients’ access to the most innovative medicines.

The Asia Group (TAG) has identified two specific pharmaceutical pricing measures that directly undermine the government’s goal of promoting startups and bringing innovative new pharmaceutical products to market. The negative impact of these policies is particularly severe for innovative drugs for rare diseases, for which there are often no alternative treatments:

  1. Strict cost disclosure requirements, especially the “co-factor zero” rule introduced in the cost-based price calculation method in 2022, are effectively canceling out many premiums that were intended to reward innovation and novelty.
  2. Corporate status criteria associated with the Price Maintenance Premium (PMP) system favor companies with a long track record of business in Japan and limit premium benefits for new market entrants.

The intended purpose of these rules is to improve transparency in a product’s total cost and provide incentives for drug launches in Japan. But the two-fold impact of these rules, particularly penalizing new market entrants and foreign entrants, has undermined the intended effect of these measures.

Eliminating these two specific punitive pricing policies represents “low-hanging fruit” for policy change, which can have an immediate impact on the availability of novel drugs, while having a relatively low impact on Japan’s healthcare budget. These changes will stimulate future successful launches and early entrance to Japan, benefitting patients.

Related Posts

美商亞洲集團宣布陳澍(George Chen)榮升合夥人
華盛頓特區及香港 | 2025年7月1日 – 美商亞洲集團(The Asia Group)欣然宣布陳澍(George Chen)晉升為集團的合夥人。陳澍將繼續領導集團在香港和台北的辦公室,並擔任TAG數位部門的聯席主席。陳澍的晉升充分展示了美商亞洲集團進一步結合頂尖全球視野與泛區域洞察的實力,也體現集團對印度-太平洋地區運營的重視,以及對客戶提供完整策略性解決方案和服務的堅定承諾。
The Asia Group Announces George Chen as Partner
Washington, DC & Hong Kong | July 1, 2025 – The Asia Group (TAG) is excited to announce the promotion ...
TAG Digital Practice Co-Chair, George Chen Spoke with Singapore’s ChannelNewsAsia about Xi Jinping, AI, and DeepSeek
George Chen, TAG Digital Practice Co-Chair, spoke with Singapore’s ChannelNewsAsia about how Chinese President Xi Jinping wanted to apply #AI to ...
TAG China Country Director, Han Lin, Comments in the Financial Times About the Significance of China Hosting the World Economic Forum “Summer Davos”
“China’s hosting of ‘Summer Davos’ amplifies how it wants to see and be seen by the international community as the ...
Scroll to Top

You Are Applying For:

TAG Paper: Observations on Drug Pricing and Innovation in Japan

Apply Now

Submit the details below, and our HR team member will get in touch with you shortly.

The Asia Group is an equal opportunity employer where an applicant’s qualifications are considered without regard to race, color, religion, sex, national origin, age, disability, veteran status, genetic information, sexual orientation, gender identity or expression, or any other basis prohibited by law. The Asia Group continually seeks to diversify its staff, particularly to broaden opportunities for individuals from demographic groups that are historically underrepresented in the strategic advisory profession.

"*" indicates required fields

1Personal Details
2Questionnaire & Application Materials
3Voluntary Self Identification

Personal Details

Name*
Address*